Sec Form 4 Filing - VAN NOSTRAND ROBERT L @ Intra-Cellular Therapies, Inc. - 2025-04-02

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person VAN NOSTRAND ROBERT L 2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ ITCI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O INTRA-CELLULAR THERAPIES, INC., 135 ROUTE 202/206, SUITE 6 3. Date of Earliest Transaction (MM/DD/YY) 04/02/2025 (Street) BEDMINSTER, NJ07921 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/02/2025 D( 1 )( 2 ) 11,340 D $ 132 ( 1 ) ( 2 ) 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 26.58 04/02/2025 D 20,000 ( 3 )( 4 ) < span class="form4-data">06/15/2025 Common Stock 20,000 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 38.35 04/02/2025 D 20,000 ( 3 )( 4 ) 06/13/2026 Common Stock 20,000 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 20.39 04/02/2025 D 20,000 ( 3 )( 4 ) 06/17/2028 Common Stock 20,000 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 22.02 04/02/2025 D 20,000 ( 3 )( 4 ) 05/26/2030 Common Stock 20,000 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 43.45 04/02/2025 D 20,000 ( 3 )( 4 ) 06/20/2031 Common Stock 20,000 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 55.48 04/02/2025 D 16,757 ( 3 )( 4 ) 06/08/2032 Common Stock 16,757 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 63.79 04/02/2025 D 7,009 ( 3 )( 4 ) 06/22/2033 Common Stock 7,009 ( 3 ) ( 4 ) 0 D Stock Option (right to buy) $ 67.77 04/02/2025 D 4,322 ( 3 )( 4 ) 06/13/2034 Common Stock 4,322 ( 3 ) ( 4 ) 0 D Restricted Stock Units ( 5 ) 04/02/2025 D 2,951 ( 6 ) ( 7 ) Common Stock 2,951 ( 6 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other VAN NOSTRAND ROBERT L C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206, SUITE 6 BEDMINSTER, NJ07921 X Signatures /s/ John P. Condon, Attorney-in-fact 04/02/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). ( 2 )(Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. ( 3 )Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. ( 4 )(Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration. ( 5 )Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. ( 6 )Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. ( 7 )Not applicable.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.